Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea-Reference-Cited by-同舟云学术

Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea

Published:2021-07-13 Issue:17 Volume:10 Page:5809-5822
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Kim Taeyun¹^ORCID,Jang Tae Won²,Choi Chang Min³,Kim Mi‐Hyun⁴,Lee Sung Yong⁵,Park Cheol‐Kyu⁶,Chang Yoon Soo⁷,Lee Kye Young⁸,Kim Seung Joon⁹,Yang Sei Hoon¹⁰,Ryu Jeong Seon¹¹^ORCID,Lee Jeong Eun¹²,Lee Shin Yup¹³,Park Chan Kwon¹⁴,Lee Sang Hoon¹⁵,Jang Seung Hun¹⁶,Yoon Seong Hoon¹⁷

Affiliation:

1. Department of Internal Medicine The Armed Forces Goyang Hospital Goyang‐si Korea

2. Department of Internal Medicine Kosin University College of MedicineKosin University Gospel Hospital Busan Korea

3. Department of Internal Medicine Ulsan University Asan Medical Center Seoul Korea

4. Department of Internal Medicine Pusan National University School of Medicine and Biomedical Research InstitutePusan National University Hospital Pusan Korea

5. Division of Pulmonology, Allergy, and Critical Care Medicine Department of Internal Medicine Korea University Guro Hospital Seoul Korea

6. Department of Internal Medicine Chonnam National University Hwasun Hospital Hwasun Korea

7. Department of Internal Medicine Yonsei University Gangnam Severance Hospital Seoul Korea

8. Department of Internal Medicine Konkuk University Medical Center Seoul Korea

9. Department of Internal Medicine Catholic University Seoul St. Mary's Hospital Seoul Korea

10. Department of Internal Medicine Wonkwang University Hospital Iksan Korea

11. Department of Internal Medicine Inha University Hospital Incheon Korea

12. Department of Internal Medicine Chungnam National University Hospital Daejeon Korea

13. Department of Internal Medicine Kyungpook National University Chilgok Hospital Daegu Korea

14. Department of Internal Medicine Catholic University Yeouido St. Mary's Hospital Seoul Korea

15. Department of Internal Medicine Yonsei University Severance Hospital Seoul Korea

16. Department of Internal Medicine Hallym University Sacred Heart Hospital Anyang Korea

17. Department of Internal Medicine Pusan National University Yangsan Hospital Yangsan Korea

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4127

Reference27 articles.

1. Prediction of Cancer Incidence and Mortality in Korea, 2018

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

4. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

5. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC;ESMO Real World Data and Digital Oncology;2024-09

2. Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?;Translational Lung Cancer Research;2024-02

3. Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinibvs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data;Anticancer Research;2023-12-30

4. Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study;Cancer Research and Treatment;2023-10-15

5. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance;Translational Lung Cancer Research;2023-04